Arundine

Summary

Arundine (CHEMBL446452) is a phase-3 clinical-stage small-molecule antineoplastic agent; indicated across 3 conditions including breast neoplasm and prostate adenocarcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 10
• Chemistry: 246.31 Da · C17H14N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL446452
Name	Arundine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	3071
ChEBI	CHEBI:50182
Molecular formula	C17H14N2
Molecular weight	246.31
InChIKey	VFTRKSBEFQDZKX-UHFFFAOYSA-N

SMILES: C1=CC=C2C(=C1)C(=CN2)CC3=CNC4=CC=CC=C43

IUPAC name: 3-(1H-indol-3-ylmethyl)-1H-indole

Pharmacological roles (ChEBI): antineoplastic agent, P450 inhibitor.

Also known as: 3,3’-diindolylmethane, Arundine, Diindolylmethane, arundine, SID26749354, SID26753756, SID26753757, 3,3’-Diindolylmethane, SID26753758, SID529850, 3,3’-DIINDOLYLMETHANE, SID174007202

Patent coverage: 961 distinct patent families (2,826 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Ferritin light chain, Menin/Histone-lysine N-methyltransferase MLL, Aryl hydrocarbon receptor, Cytochrome P450 3A4, G-protein coupled receptor 84, G-protein coupled receptor 84, Aryl hydrocarbon receptor.

Bioactivity

ChEMBL activities: 16 potent at pChembl ≥ 5 of 29 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P30561	7.05	Kd	90	nM	CHEMBL_ACT_18925188
AHR	7.05	Kd	90	nM	CHEMBL_ACT_25059573
GPR84	6.6	EC50	252	nM	CHEMBL_ACT_18070583
GPR84	6.43	EC50	368	nM	CHEMBL_ACT_19003544
GPR84	6.3	EC50	500	nM	CHEMBL_ACT_19003359
GPR84	6.16	EC50	700	nM	CHEMBL_ACT_19003358
GPR84	6	EC50	1000	nM	CHEMBL_ACT_19003365
GPR84	5.96	EC50	1110	nM	CHEMBL_ACT_19003392
GPR84	5.9	EC50	1260	nM	CHEMBL_ACT_19003370
GPR84	5.79	EC50	1640	nM	CHEMBL_ACT_18070710
GPR84	5.54	EC50	2880	nM	CHEMBL_ACT_18070862
Q8CIM5	5.37	EC50	4270	nM	CHEMBL_ACT_22804590
GPR84	5.29	EC50	5120	nM	CHEMBL_ACT_18070861
GPR84	5.23	EC50	5900	nM	CHEMBL_ACT_19003373
GPR84	5.2	EC50	6280	nM	CHEMBL_ACT_18070859
GPR84	5.08	EC50	8370	nM	CHEMBL_ACT_18070857

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
breast neoplasm	2	MONDO:0021100	MONDO:0007254
prostate adenocarcinoma	1	MONDO:0005082	EFO:0000673

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE1	4
Not specified	3
PHASE3	1
PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00462813	PHASE3	COMPLETED	Diindolylmethane in Treating Patients With Abnormal Cervical Cells
NCT01612910	PHASE2	WITHDRAWN	Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery
NCT00392652	PHASE1	COMPLETED	Diindolylmethane in Healthy Volunteers
NCT00450229	PHASE1	COMPLETED	Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer
NCT00784394	PHASE1	COMPLETED	Diindolylmethane in Preventing Cancer in Healthy Volunteers
NCT01022333	PHASE1	UNKNOWN	The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers
NCT01846364	EARLY_PHASE1	TERMINATED	DIM as a Treatment for Thyroid Disease
NCT00591305	Not specified	TERMINATED	New Therapy of Laryngeal Papilloma In Children
NCT01391689	Not specified	COMPLETED	Diindolylmethane in Treating Patients With Breast Cancer
NCT04292236	Not specified	COMPLETED	The Effect of Food Supplements on Food Intake and Gut Hormone Levels

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).